Skip to main content

Lara Hathout, MD

Division of Clinical Radiation Oncology

Radiation Oncology has been a passion of mine from my first year in medical school. My first clinical rotation was an elective in radiation oncology that changed my perspective on cancer care. I witnessed firsthand the importance of patient-focused care, with empathy and bedside manner that guided and fueled my continued interest in this field of medicine. My primary goal as a radiation oncologist is to deliver treatment with cutting-edge technology while minimizing side effects and tailoring the treatment to the patients’ needs. I am a Board Certified radiation oncologist in the Department of Radiation Oncology at the Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School. I completed a Brachytherapy Fellowship at the Memorial Sloan-Kettering Cancer Center in June 2014 after completing my medical training and a residency in Radiation Oncology at University of Montreal in Montreal, Canada. Prior to joining Rutgers Cancer Institute, I served as a Clinical Instructor of Radiation Oncology at the Université de Laval at Centre Hospitalier Universitaire de Québec in Quebec City, Canada. My clinical sites are Gynecologic and genitourinary cancers. I offer patients state-of-the-art treatment with leading edge technologies through my expertise in Brachytherapy, Intensity Modulated radiation therapy (IMRT), Stereotactic Body radiotherapy (SBRT) and Proton Beam Therapy. In addition to English I speak fluent French, Spanish and Arabic. In addition to my clinical practice I continue to be active in clinical research. I am the primary investigator of several clinical trials at CINJ. As a peer reviewer for the Brachytherapy Journal, American Brachytherapy Society and American Society of Therapeutic Radiation Oncology, I am committed to publishing and educating both my peers and patients in treatment options while guiding them to make informed decisions on optimal care.

 

Publications
  1. PSA outcomes and late toxicity of single-fraction HDR brachytherapy and LDR brachytherapy as monotherapy in localized prostate cancer: A phase 2 randomized pilot study. Reynaud T, Hathout L, Carignan D, Barkati M, Martin AG, Foster W, Lacroix F, Delouya G, Taussky D, Morton G, Vigneault E. Brachytherapy. 2021 Jul 5:S1538-4721(21)00106-9. doi: 10.1016/j.brachy.2021.05.010.
  2. A Multi-Institutional Analysis of Adjuvant Chemotherapy and Radiation Sequence in Women With Stage IIIC Endometrial Cancer. Hathout L, Wang Y, Wang Q, Vergalasova I, Elshaikh MA, Dimitrova I, Damast S, Li JY, Fields EC, Beriwal S, Keller A, Kidd EA, Usoz M, Jolly S, Jaworski E, Leung EW, Donovan E, Taunk NK, Chino J, Natesan D, Russo AL, Lea JS, Albuquerque KV, Lee LJ. Int J Radiat Oncol Biol Phys. 2021 Aug 1;110(5):1423-1431. doi: 10.1016/j.ijrobp.2021.02.055. Epub 2021 Mar 5. PMID: 33677053
  3. The Impact of COVID-19 on Brachytherapy During the Pandemic: A Rutgers-Robert Wood Johnson Barnabas Health Multisite Experience. Hathout L, Ennis RD, Mattes MD, Wagman RT, Grann A, Jabbour SK, Singh R, Yue NJ, Haffty BG, Vergalasova I. Adv Radiat Oncol. 2021 Jan-Feb;6(1):100600. doi: 10.1016/j.adro.2020.10.013. Epub 2020 Nov 2. PMID: 33163697
  4. Stereotactic body radiation therapy for oligometastatic gynecologic malignancies: A systematic review. Yegya-Raman N, Cao CD, Hathout L, Girda E, Richard SD, Rosenblum NG, Taunk NK, Jabbour SK. Gynecol Oncol. 2020 Nov;159(2):573-580. doi: 10.1016/j.ygyno.2020.08.010. Epub 2020 Sep 9. PMID: 32917412
  5. A Phase 2 Randomized Pilot Study Comparing High-Dose-Rate Brachytherapy and Low-Dose-Rate Brachytherapy as Monotherapy in Localized Prostate Cancer. Hathout L, Mahmoud O, Wang Y, Vergalasova I, Barkati M, Després P, Martin AG, Foster W, Lacroix F, Delouya G, Taussky D, Morton G, Vigneault E. Adv Radiat Oncol. 2019 Apr 18;4(4):631-640. doi: 10.1016/j.adro.2019.04.003. eCollection 2019 Oct-Dec